Scientists have made significant steps in the development of vaccines that could be used to tackle COVID-19 in animals.
The Vaccine Group, a spinout company from the University of Plymouth, has revealed its first two possible vaccines have proved successful in pre-animal trial laboratory testing.
Its aim is to now develop vaccines so as to eliminate SARS-CoV-2 (the virus that causes COVID-19) in existing animal sources.
The vaccines could also be used to ensure cats, which have already been shown to become infected with SARS-CoV-2, and other pets do not become a reservoir for future outbreaks.
The company is also investigating the longer-term potential of human vaccines and the next stage of development will be vital in assessing the technology’s safety and efficacy for use in humans.
Dr Michael Jarvis, Associate Professor (Reader) in Virology and Immunology at the University of Plymouth, is The Vaccine Group’s Founder and Chief Scientific Officer. He said: